Related Experiment Video

Updated: Jun 3, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Different effect of IgA nephropathy and polycystic kidney disease on arterial stiffness

István Késoi1, Balázs Sági, Orsolya I Tóth

  • 1Nephrology Center and 2nd Department of Internal Medicine, University of Pécs, 1 Pacsirta St., Pécs, Hungary.

Kidney & Blood Pressure Research
|April 9, 2011
PubMed

Insights

Patients with chronic kidney disease (CKD) exhibit increased arterial stiffness. Polycystic kidney disease (PKD) shows more pronounced arterial stiffening than IgA nephropathy (IgAN), highlighting blood pressure as a key therapeutic target.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Vascular Biology

Background:

  • Renal function significantly impacts vascular health and cardiovascular disease risk.
  • Limited data exists on how specific renal diseases affect vascular function in chronic kidney disease (CKD).

Purpose of the Study:

  • To investigate and compare vascular function, specifically arterial stiffness, in patients with IgA nephropathy (IgAN) and polycystic kidney disease (PKD).
  • To determine the relationship between arterial stiffness and kidney function across different etiologies of CKD.

Main Methods:

  • Studied 120 CKD patients (60 IgAN, 60 PKD) across stages 1-4.
  • Measured pulse-wave velocity using the digital volume pulse (DVP) method to derive the stiffness index (SI(DVP)).

Main Results:

  • CKD patients (IgAN and PKD) demonstrated significantly increased SI(DVP) compared to controls.
  • Polycystic kidney disease (PKD) patients exhibited greater arterial stiffness (SI(DVP)) than IgA nephropathy (IgAN) patients and controls.
  • A significant inverse correlation was observed between SI(DVP) and glomerular filtration rate in IgAN patients, but not in PKD patients. Age and 24-hour systolic blood pressure were independent predictors of SI(DVP).

Conclusions:

  • Arterial stiffness is elevated in CKD patients, with a more pronounced effect in PKD compared to IgAN.
  • Vascular function is differentially affected by distinct etiologies of CKD.
  • Elevated blood pressure represents a critical, modifiable risk factor for arterial stiffening in CKD.
Abstract

More Related Videos

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy10:35

Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy

Published on: October 19, 2016

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound10:08

Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound

Published on: December 2, 2014

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...